Saphris: Medgend

Saphris FDA Approved Drugs

SAPHRIS [Asenapine Maleate^{C₁₇H₁₆ClNOC₄H₄O₄}]

eq 10mg base (sublingual tablet)

eq 2.5 base (sublingual tablet)

eq 5mg base (sublingual tablet)

Forest Labs Llc^{Aug 13, 2009}

Method of treating manic or mixed episodes associated with bipolar disorder in pediatric patients.
Method of treating schizophrenia and bipolar disorder.
Treatment of bipolar disorder and schizophrenia.
Use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: acute monotherapy of manic or mixed episodes (ages 10 to adult).
Use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: acute monotherapy of manic or mixed episodes in pediatric patients age 10-17.
Use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: as adjunctive treatment to lithium or valproate in adults.
Use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: maintenance monotherapy in adults.
Use of the atypical antipsychotic asenapine for treatment of schizophrenia in adults.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.